Welcome to our dedicated page for Senti Bioscience SEC filings (Ticker: SNTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Senti Biosciences, Inc. (Senti Bio) (NASDAQ: SNTI) SEC filings page provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company and emerging growth company, Senti Bio uses these filings to report on its financial condition, corporate governance matters, and progress across its cell and gene therapy programs built on its Gene Circuit platform.
Current and periodic reports such as Forms 10-Q and 10-K (when available) typically include detailed discussions of research and development activities, risks related to clinical-stage operations, and updates on key programs like SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy product candidate for CD33 and/or FLT3 expressing hematologic malignancies including AML and MDS. These reports also describe the company’s status as an emerging growth company and provide information on cash, operating expenses, and accumulated deficit.
Form 8-K filings capture material events, including quarterly financial result announcements and outcomes of the annual meeting of stockholders. For example, recent 8-Ks reference press releases on financial results and describe voting results for director elections and auditor ratification. Investors use these documents to track significant corporate developments beyond scheduled periodic reports.
Through this page, users can also review proxy statements and related governance materials, which explain matters submitted to stockholders, such as board composition and auditor selection. Insider transaction reports on Form 4, when present, provide visibility into equity transactions by directors and officers.
Stock Titan enhances access to these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify disclosures on clinical programs, Gene Circuit platform risks, and financial trends. Real-time updates from EDGAR ensure that new SNTI filings, from 10-K and 10-Q reports to 8-K current reports and Forms 3 and 4, are surfaced as they become available.
Senti Biosciences Holdings, Inc. filed a Post-Effective Amendment No. 1 to its Form S-3 to reflect a holding company reorganization completed on April 24, 2026. The Successor Registrant expressly adopts the existing Registration Statement (No. 333-285985) under Rule 414. No additional securities are being registered by this Amendment. The filing describes the Merger Agreement effectuating the reorganization, confirms a one-for-one conversion of Predecessor common shares into Successor common shares, and incorporates the Successor’s amended certificate of incorporation and bylaws. The document also recites indemnification provisions, advancement of expenses, and indemnification agreements for officers and directors.
Senti Biosciences Holdings, Inc. filed a Post-Effective Amendment No. 1 to its Form S-3 on April 24, 2026 reflecting a holding company reorganization completed the same day. The amendment states that each outstanding share of the predecessor's common stock was converted into one share of the successor's common stock, and no additional securities are being registered by this amendment. The successor adopted organizational documents substantially identical to the predecessor's and expressly adopts the Registration Statement (File No. 333-285983) pursuant to Rule 414.
Senti Biosciences Holdings, Inc. filed Post-Effective Amendment No. 2 to its registration statement (Registration No. 333-265873) to reflect a holding company reorganization completed on April 24, 2026. The amendment states that 2,000,000 Earn-Out Shares originally registered are no longer issuable and have been removed from registration. The Successor Registrant adopted organizational documents substantially identical to the Predecessor and expressly adopts the prior registration statement under Rule 414. No additional securities are being registered pursuant to this amendment.
Senti Biosciences, Inc. files Post-Effective Amendment No. 2 to remove from registration the resale of 8,727,049 shares of its common stock previously registered for resale by Chardan Capital Markets LLC.
The amendment states the Registrant is no longer required to register the resale under the Registration Rights Agreement and has terminated the related offering.
Bayer HealthCare LLC and affiliated reporting persons filed an amended Schedule 13D showing a significant ownership position in Senti Biosciences, Inc. They report beneficial ownership of 6,142,848 shares of common stock, representing 17.82% of the company.
This total includes 3,333,000 shares underlying a warrant for Senti common stock that is exercisable in full within 60 days of the filing date. The ownership percentage is based on 31,144,497 Senti common shares outstanding as of March 19, 2026, as reported in the company’s Form 10-K.
Senti Biosciences, Inc. plans a tax-free holding company reorganization, targeted to become effective by April 16, 2026. The company would merge into a new subsidiary, with Senti Biosciences Holdings, Inc. becoming the successor issuer.
Each existing share of Senti common stock would automatically convert into an equivalent share of Senti Biosciences Holdings common stock with the same rights. Shares would continue trading on the Nasdaq Capital Market under the symbol SNTI with a new CUSIP number, and stockholders are expected not to recognize gain or loss for U.S. federal income tax purposes. Directors, officers, assets, businesses and operations would remain the same after the reorganization, though the company may decide not to complete it or could delay completion.
New Enterprise Associates 15, L.P. and affiliated entities report an updated ownership position in Senti Biosciences, Inc. They beneficially own 3,775,615 shares of Senti’s common stock, representing 12.1% of the outstanding shares based on 31,144,497 shares outstanding as of March 19, 2026. The filing states that this Amendment No. 3 is being made because their percentage ownership decreased by more than 1% due to an increase in Senti’s shares outstanding, not because of recent share sales or purchases. NEA 15 acquired the shares for investment purposes and may buy or sell additional shares in the future depending on market conditions and its evaluation of the company, but it currently has no specific plans for corporate actions such as mergers, board changes, or major asset sales.
Senti Biosciences, Inc. is a clinical-stage biotech company developing gene circuit–enabled cell and gene therapies, with a primary focus on oncology. Its lead program, SENTI-202, is an off-the-shelf CAR-NK cell therapy for relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML).
In a Phase 1 trial, SENTI-202 showed a 50% overall response rate in twenty AML patients, with 42% achieving complete remission or CRh and most remissions being MRD-negative at the recommended Phase 2 dose. The FDA granted SENTI-202 Orphan Drug and RMAT designations, reflecting its potential in a high‑need setting.
The company is expanding its pipeline using a modular gene circuit platform (Logic Gating, Multi-Arming, Regulator Dials, Smart Sensors) across NK, T cells, and gene therapy modalities, and maintains collaborations with partners such as BlueRock Therapeutics and Celest Therapeutics, plus multiple NCI license agreements. As of March 19, 2026, Senti had 31,144,497 common shares outstanding and a non‑affiliate market value of approximately $53.2 million as of June 30, 2025.
Senti Biosciences, Inc. reported 2025 results and highlighted key clinical progress, led by SENTI-202 in relapsed or refractory acute myeloid leukemia. The program generated updated positive preliminary Phase 1 data with encouraging response rates, durability and a favorable safety profile, and received U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) designation.
As of December 31, 2025, Senti Bio held $16.4 million in cash and cash equivalents, with total assets of $51.2 million and total liabilities of $45.6 million. For full-year 2025, research and development expenses were $37.6 million and general and administrative expenses were $26.2 million. The company recorded a net loss of $61.4 million, or $2.73 per share, including a non-recurring $5.1 million impairment of long-lived assets and $5.7 million of non-cash stock-based compensation.
Senti Biosciences, Inc. entered into a series of agreements to restructure its facility lease and related sublease for its Alameda, California premises. Effective September 1, 2025, the company will reduce its leased space from approximately 91,910 to 45,955 rentable square feet, cutting its proportionate share of operating expenses and taxes to 50% while keeping responsibility for all utilities until the surrendered space is re-let.
The amended lease sets stepped monthly base rent for the remaining premises, starting at $188,311 from September 1, 2025 through July 31, 2026 and rising over time to $293,010 for August 2022. As consideration for this rent reduction, the landlord may draw $2.0 million on the company’s existing $2.76 million letter of credit, after which the required letter of credit amount drops to $760,000.
The company also amended its sublease with GeneFab, LLC so the subleased space and GeneFab’s payment obligations mirror the amended lease economics, and entered into a consent and letter agreement. GeneFab will pay a $1.0 million reduction fee to the landlord and has $1,374,005 of outstanding base rent that can be satisfied through a prepayment credit for future work or services, with any unpaid portion due by September 1, 2026. GeneFab’s failure to perform on these obligations constitutes an immediate event of default under the amended sublease.